InvestorsHub Logo
Followers 244
Posts 12705
Boards Moderated 0
Alias Born 08/14/2003

Re: danielboog2 post# 489163

Wednesday, 06/22/2022 5:26:10 PM

Wednesday, June 22, 2022 5:26:10 PM

Post# of 721524
Daniel,

I believe that DI's job description is probably just fine, but with the quiet period he has been handcuffed for years. I suspect that when the handcuffs are removed he'll do a fine job in getting NWBO's story out there.

Several years ago my daughter worked for a major New York PR firm on the rollout of a new cancer drug from a BP. You'd be surprised how much their hands were tied as many of their ideas on promoting the new drug were shot down. Companies regardless of their size are often overly cautious about what they're willing to say even when trial results are outstanding.

Results that we've seen to date show that DCVax-L more than doubles what patients could expect before it, but unfortunately that's still not that much, but it's true. I doubt that they'll advertise that the better than double the anticipated outcome. Frankly that may not be as important as the fact that DCVax-L appears to open the door to other drugs like Keytruda being effective, whereas without it they aren't. I.E. they're opening the door to other treatments being more effective, no telling how far opening that door will take patients.

Gary
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News